Search

everythinglearnresearchcommunity

for

Search:↓

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

Hedgehog pathway inhibitors can treat certain aggressive cancers but face limitations like resistance and side effects.

Personalized treatment with inhibitors, minoxidil, and laser therapy helps hair loss.

5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.

5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.

S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.

The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.

Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.

5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.

5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.

Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.

Using 5-alpha reductase inhibitors may increase the risk of mild depression.

Older patients sticking to their prostate medication saw lasting health benefits.

Light therapy is effective and safe for treating skin color disorders like vitiligo and dark spots.

Dutasteride and finasteride can help increase hair growth gene expression but need further improvement.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.

5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

Finasteride treats hair loss and reduces prostate cancer risk.

Managing diabetes can lead to eating disorders, and eating disorders can make diabetes harder to control.

Beta-sitosterol and stigmasterol might help prevent hair loss by blocking a specific enzyme.

Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.

Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.

C60 fullerenes can alter protein function and may help develop new disease inhibitors.

Plant-based products can improve hair and skin health without harmful side effects.

A new method was created to test the effectiveness of Dihydrotestosterone (DHT) inhibitors, like finasteride and dutasteride, in human and fish cells. The results showed fish cells are more sensitive to these treatments, and dutasteride works better than finasteride in all tested cells.

The document concludes that H2-antagonists and proton pump inhibitors are highly effective for ulcers, eradicating Helicobacter pylori is important to prevent recurrence, and misoprostol helps with NSAID-related ulcers.

Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.